Overview
Pelthos Therapeutics Inc experienced a 5.7% increase in its share price on Tuesday following a disclosed stock purchase by company director Todd C. Davis. According to a Form 4 filing with the Securities and Exchange Commission, Davis acquired 35,948 shares of common stock on June 11 for approximately $999,980. The filing lists weighted average execution prices ranging from $27.8046 to $28.7261 per share.
Details of the purchase
The transactions were completed across multiple trades. The filing specifies a primary transaction involving 35,445 shares executed at prices between $27.63 and $28.49, and a secondary transaction of 503 shares executed at prices between $28.72 and $28.94. The aggregate purchase is identified as the second largest of six acquisitions recorded by Davis to date.
Post-transaction holdings
After these trades, Davis directly holds 75,834 shares of Pelthos Therapeutics common stock. In addition to his direct ownership, the filing notes that Davis has indirect beneficial ownership of 1,500,000 shares of Pelthos stock held by Ligand Pharmaceuticals Incorporated, where he serves as Chief Executive Officer and a board member. The filing also states that Davis disclaims beneficial ownership of the Ligand-held shares except to the extent of his pecuniary interest.
Execution and price range
The Form 4 filing makes clear that the purchases were executed in multiple trades spanning a modest range of prices. The two reported groupings of trades show a variation in execution prices, with the larger tranche carried out between $27.63 and $28.49 and the smaller tranche between $28.72 and $28.94. The weighted average prices for the combined purchase lie between $27.8046 and $28.7261 per share.
Key points
- Pelthos Therapeutics shares rose 5.7% on Tuesday after a director-level stock purchase.
- Todd C. Davis bought 35,948 shares on June 11 for about $999,980 at weighted average prices from $27.8046 to $28.7261.
- Davis directly owns 75,834 shares and has indirect beneficial ownership of 1,500,000 shares through Ligand Pharmaceuticals, where he is CEO and board member.
Risks and uncertainties
- Price variability during execution - the purchases were executed across a range of prices, indicating short-term trade-level volatility in the executed transactions.
- Limited clarity on beneficial ownership - Davis disclaims beneficial ownership of the Ligand-held shares except to the extent of his pecuniary interest, which affects the degree of his control or influence over those 1,500,000 shares.
- Concentration of reported buying activity - the filing notes these transactions as the second largest of six purchases by Davis, which highlights reliance on a small number of disclosed acquisitions when assessing insider buying patterns.
Sectors affected
- Biotechnology - Pelthos Therapeutics operates within the biotech sector, and the reported insider purchase and share movement relate to trading dynamics in that market.
- Equity markets - the disclosed trades and subsequent stock price change reflect developments relevant to investors and market participants monitoring insider activity.